RT Journal Article SR Electronic T1 Characterization of Dopaminergic Receptors in Dispersed Bovine Parathyroid Cells JF Molecular Pharmacology JO Mol Pharmacol FD American Society for Pharmacology and Experimental Therapeutics SP 335 OP 340 VO 18 IS 3 A1 E. M. BROWN A1 M. F. ATTIE A1 S. REEN A1 D. G. GARDNER A1 J. KEBABIAN A1 G. D. AURBACH YR 1980 UL http://molpharm.aspetjournals.org/content/18/3/335.abstract AB Several dopaminergic ligands were assessed for their effects on cAMP accumulation, adenylate cyclase activity, and parathyroid hormone (PTH) release from dispersed bovine parathyroid cells. Dopamine, 6,7-dihydroxy-1,2,3,4 tetrahydronaphthalene (ADTN), 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine (SKF-38393), and apomorphine increased cAMP content 30-, 25-, 10-, and 2- to 3-fold with Ka’s of 0.6, 0.5, 1, and 1-3 µM, respectively. These same agents also stimulated adenylate cyclase activity up to 4-fold and PTH release 1.3- to 3-fold. With the exception of lisuride (Ki = 15 nM), ergot derivatives were of relatively low potency (Ki’s = 0.4-20 µM) in inhibiting dopamine-stimulated cAMP accumulation. Similar Ki’s were observed for effects on dopamine-stimulated adenylate cyclase activity and PTH release. Interactions of these ligands with the dopamine receptor could be clearly differentiated from effects of β-adrenergic or α-adrenergic receptors also known to modulate cAMP accumulation and secretion in this cell type. These results demonstrate the presence of a D-1 dopaminergic receptor on bovine parathyroid cells and document further the relationship in this receptor subclass between adenylate cyclase activity, cAMP accumulation, and a biologic response.